Physician profile
Kim E Goldinger
NPI 1982910758
$1,428.19
in general payments reported to CMS, 2019-2025
9 companies · $513 in 2025
The $513 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $185 · 2023: $98.30 · 2024: $507 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,118.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $458.44 | 2021-2025 | Wegovy, Ozempic |
| Abbvie INC. | $197.81 | 2022-2023 | |
| Edwards Lifesciences Corporation | $162.78 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amgen INC. | $139.48 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $124.99 | 2025 | Rexulti |
| Biosense Webster, INC. | $94.61 | 2024 | Carto 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.43 | 2022 | |
| Gilead Sciences, INC. | $85.02 | 2024 | Epclusa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $79.63 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Goldinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.